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Abstract
One of the promising approaches for designing HIV vaccines is construction of synthetic 
polyepitope HIV-1 immunogen using a wide range of conservative T- and B-cell epitopes 
of the main virus antigens. In theory this approach helps cope with HIV-1 antigenic vari-
ability, focuses immune responses on protective determinants and enables to exclude 
from the vaccine compound adverse regions of viral proteins that can induce autoanti-
bodies or antibodies enhancing infectivity of virus. The paper presents the experience of 
our team in development of artificial polyepitope HIV-1 immunogens, which can induce 
both a humoral response, and responses of cytotoxic (CD8 + CTL) and helpers (CD4 + Th) 
T-cells. The design of HIV-immunogens has been done using our original software, 
TEpredict and PolyCTLDesigner. We describe development of the candidate HIV-1/
AIDS vaccine – CombiHIVvac, which included two artificial polyepitope immunogens 
TBI and TCI for stimulating humoral and cellular responses. The results of the specific 
activity and safety of CombiHIVvac vaccine, obtained during preclinical and clinical tri-
als, are presented.
Keywords: HIV-1 vaccine, artificial polyepitope T- and B-cell immunogens, rational 
design, preclinical and clinical trials
1. Introduction
For over 200 years a vaccine development effort was to isolate microbes or viruses and prepare 
a killed or attenuated pathogen vaccine. For many self-limiting bacterial and viral  infections 
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the vaccine strategy is to mimic the infectious process and natural immunity against a par-
ticular pathogen. However, for HIV-1 and for many other chronic viral, bacterial, fungal and 
parasitic infections, and cancer natural immunity is insufficient for protection [1, 2]. Novel 
and effective approaches in polyepitope HIV-vaccine development are needed today [3, 4].
Problems that retard development of HIV-1 vaccine are well-known. Firstly, HIV-1 has a high 
rate of escape mutations with the result that the virus can change the antigenic structure 
quicker than the immune system is switched to new antigenic variants. Secondly, it is still 
unclear which type of immune response is more significant when preventing infection: induc-
tion of HIV neutralizing antibodies (in systemic vs. mucosal compartments), CD4+ T-helper 
cells, cytotoxic CD8+ T-cells (both potent high avidity CD8+ T-effector/memory responses and 
central memory responses), innate immunity, or all factors together. However, recent publica-
tions demonstrate that a humoral response to vaccine may be critical to prevent acquisition of 
HIV, while CD8+ T-cells may be required to control viral replication in vaccinated individual. 
Thirdly, virus proteins include regions with pathogenic properties due to molecular mim-
icry of physiologically significant functions or induction of autoimmune responses that might 
contribute to immunodeficiency. Finally, when studying HIV-infection, experimental models 
are very limited [1, 5–7].
Well-known HIV-1 vaccine design strategies are based on the use of different forms of viral 
antigen including inactivated virus, modified or attenuated virus, native and genetically engi-
neered proteins, and peptides [5]. The first generation candidate vaccines (such as AIDSVAX 
B/B and AIDSVAX B/E) were constructed for inducing humoral immunity, to elicit virus-
neutralizing antibodies. Development of such vaccines was based on the use of full-length 
proteins of HIV envelope or their fragments [8]. The second generation vaccines (e.g. Merck 
Ad5 gag/pol/nef of B subtype) were aimed to mediate protection by inducing HIV-specific 
cytotoxic T-lymphocytes (CTLs) capable to recognize and eliminate HIV-infected cells [9]. 
Many candidates were tested in human or animals; however, none of them has demonstrated 
efficacy in phase II-III trials [10].
The first promising and statistically significant results were obtained in clinical trials of RV144 
vaccine stimulating both humoral and cellular immunity. It is a combination of two previ-
ously developed vaccines ALVAC-HIV (Sanofi Pasteur) and AIDSVAX B/E gp120 (VAXGEN) 
[11]. Despite rather low protective efficacy (31.2%), RV144 clinical trials made it possible to 
draw several weighty conclusions, i.e. (1) HIV-1 vaccine is not a myth but a reality; (2) efficient 
vaccine should induce both humoral and cell immune responses against HIV-1, and (3) new 
approaches are needed to increase vaccine efficacy [2, 3, 12].
One of them includes construction of completely artificial polyepitope (mosaic) anti-HIV-1 
immunogens comprising a broad range of protective T- and B-cell epitopes based on the main 
viral antigens capable of inducing production of neutralizing antibodies and responses of 
cytotoxic (CD8+ CTL) and helper (CD4+ Th) T-lymphocytes. This approach seems to be rather 
promising when developing new generation HIV-vaccines. In theory, it makes it possible to 
overcome HIV-1 antigenic variability, focus immune responses on protective epitopes and 
allows to exclude undesirable determinants from a vaccine compound capable of inducing 
autoantibodies or antibodies increasing virus infectivity [3, 4, 13]. This paper discusses our 
experience in designing artificial polyepitope antigens – HIV-1 candidate vaccines.
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2. Artificial TBI and TCI immunogens
The first immunogen designed in our project, short for T- and B-cell epitopes containing 
Immunogen (TBI), was constructed with the use of conservative epitopes from Env and Gag 
HIV-1 based on a well-known protein space motif, i.e. four helix bundle (Figure 1). When 
designing immunogen, four Th-cell epitopes (amphipathic α-helix) and five B-cell epitopes 
(regions with flexible hydrophilic loops) were used as blocks [14, 15]. The rationale for TBI 
design was that combining T- and B-cell epitopes in one construct will stimulate both proper 
B-cell and T-cell responses and the necessary interplay between B- and T-cells. Recombinant 
protein TBI has a CD spectra similar to ones in α-helical proteins and was able to form crystals 
- that was demonstrated for artificial protein with a predicted tertiary structure for the first 
time [16]. Based on its ability to crystallize we assumed that TBI protein structure is similar to 
that of the natural proteins.
Mice and Macaque rhesus immunized with TBI formed both cell and humoral responses to 
HIV-1. TBI-induced antibodies showed virus-neutralizing activity to HIV-1 [17].
The second artificial polyepitope immunogen we developed was TCI (short for T-Cell 
Immunogen) aimed at stimulation of T-cell immunity [18]. When constructing immunogen, 
we selected highly conservative T-cell epitopes among three main HIV-1 subtypes (A, B, and 
C) (Figure 2). TCI comprises more than 80 T-cell epitopes (both CD8+ CTL and CD4+ Th) from 
Env, Gag, Pol, and Nef proteins [18]. We analyzed CTL-epitopes that were together restricted 
with 10 different optimally selected alleles of human MHC class I. As known, it is sufficient 
to cover genetic diversity of MHC class I antigens in population from almost all geographic 
regions. Since antigen processing and presentation through MHC class I pathway were found 
to be the most efficient for proteins synthesized inside the cell, the target vaccine construct 
was designed in the form of DNA-vaccine via cloning a gene encoding TCI protein into vector 
plasmid pcDNA3.1 [18].
The obtained DNA-vaccine pcDNA-TCI was used for genetic immunization; we showed that 
the vaccine is capable of inducing both specific T-cell responses and specific antibodies in 
immunized BALB/c mice [18–20].
Figure 1. A model of TBI protein tertiary structure. T-cell epitopes are located in the region of α-helices, B-cell epitopes 
are located at loop sites and N- and C-terminuses.
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In the following, recombinant protein TBI and plasmid pcDNA-TCI were used for the devel-
opment of CombiHIVvac vaccine [21].
3. CombiHIVvac: a combined vaccine containing two immunogens 
in a single construct. Preclinical and clinical trials
Since an effective immunoprophylactic vaccine against HIV-infection must induce specific 
humoral and T-cell immune responses [2, 3, 12], we constructed CombiHIVvac vaccine com-
prising both above mentioned immunogens, i.e. TBI and TCI [21].
CombiHIVvac was constructed in the form of micelle-like particles based on the original tech-
nique combining two different immunogens in a single construct, i.e. polyepitope TBI protein 
and DNA-vaccine pcDNA-TCI encoding polyepitope protein TCI [19, 21] (Figure 3).
TBI protein is conjugated to dextran and mixed with DNA, which leads to formation of mic-
roparticles presenting TBI on the surface and containing the DNA inside. Positively charged 
spermidine provides the binding of the conjugate dextran/protein TBI with negatively charged 
DNA-vaccine promoting formation of particles on the self-assembly principle (50–250 nm in 
diameter) [22].
We have previously shown that by combining two immunogens (TBI and TCI) in one construct 
significant enhancement HIV-specific B cell response was observed [23]. In our opinion, the for-
mation of such particles plays a critical role in the registered effect. CombiHIVvac particles enable 
more effective absorption by antigen-presenting cells (APCs) compared to individual immuno-
gens. Since TBI protein is fixed on the particle surface and is represented in multiple copies, this 
Figure 2. Design of the CTL immunogen, a candidate for the in HIV-1 vaccine: a general schematic. The bar patterns 
indicate the polyepitope CTL immunogen and the origin of the sequences. The positions of individual epitopes and their 
MHC restrictions (HLA-A, B, Cw – human; H-2a, b, d, f, k, p, u, q – mouse; Mamu-A*01 – Macaca mulatta) are depicted 
as lines below the CTL immunogen. Th stands for helper epitopes.
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provides multiple enhancement of vaccine antigenicity. Besides, pcDNA-TCI enclosed in the vac-
cine structure is more protected against degradation by DNase I than free pcDNA-TCI, as it was 
previously demonstrated, resulting in prolongation of DNA-vaccine presence in an organism. 
Finally, the presence of CD4+ T-helper epitopes in the protein TCI may be the main reason under-
lying the increased synthesis of antibodies to TBI protein due to a CD4-mediated stimulation of 
B-cell proliferation and differentiation.
To carry out CombiHIVvac preclinical and clinical trials, we produced experimental series 
of vaccine of the standard quality according to WHO recommendations. Preclinical studies 
indicating the safety of the vaccine in tests with animals have been performed, namely, the 
acute and chronic toxicity has been studied in mice and guinea pigs and the absence of devia-
tions in the vital organs of animals, as well as no changes in hematological and morphological 
parameters and no immunotoxicity and allergenic activity, have been shown for both single 
and tenfold administration of vaccine. Specific activity was evaluated based on the param-
eters of humoral and cellular immunity in BALB/c mice after their twofold immunization. The 
CombiHIVvac vaccine has been shown to induce formation of HIV-specific antibodies and 
CTLs [19, 21, 24, 25]. The vaccine did not cause any pyrogenic reaction in rabbits and did not 
affect the central nervous system and the detoxification liver function in mice. The duration of 
vaccine persistence in the organisms of laboratory animals has also been estimated and it has 
been shown that such vaccine component as the plasmid DNA completely eliminated from 
the organs and tissues of mice for 2 months after vaccination [21]. Thus, preclinical studies 
showed that CombiHIVvac is safe in animal trials.
Phase I clinical trials were carried out in healthy volunteers to study reactogenicity, safety, 
and immune activity of CombiHIVvac. The results of clinical trials published in [26] 
Figure 3. TEM images of CombiHIVvac microparticles with different magnification. A – scale bar 1000 nm, the insert in 
the left upper corner is a scheme of a CombiHIVvac particle (1 – pcDNA-TCI, 2 – spermidine/dextran, 3 – TBI).
Artificial Epitope-Based Immunogens in HIV-Vaccine Design
http://dx.doi.org/10.5772/intechopen.77031
209
 demonstrated that CombiHIVvac is well-tolerated and safe. Neither single nor twofold 
(with 28-days interval) intramuscular vaccine administration induced significant changes 
in biochemical and physiological indicators as compared to the baseline values. Local reac-
tions to vaccine administration were absent. There were no pathological changes in volun-
teers for all observation time. The mean values of the examined biochemical and clinical 
parameters were within the physiological ranges or near their limits. We failed to detect any 
regularity in changes of indicators depending on the time from the date of immunization. 
All studied indicators of immune status came back to the baseline level registered before 
the vaccination [26].
When carrying out Phase I clinical trials, we assessed CombiHIVvac specific activity in addi-
tion to its safety. The obtained results revealed that CombiHIVvac induces both humoral 
and cell HIV-specific immune responses. It was was confirmed by several methods includ-
ing immunoblotting, ELISA, env-pseudotyped virus neutralization assay, IFN-γ ELISpot and 
peptide-МНС-pentamers.
The specific immune response was detected via ELISA 14 days after the first immunization; 
the second immunization led to enhance the immune response. The maximum immune 
response is observed by ELISA on the 14th day after the second vaccine administration. Up to 
the end of observation time (1 year) we detected antibodies in 29% of volunteers.
To confirm antibody production capable of recognizing native HIV-1 during CombiHIVvac 
administration, we used a kit “New Lav blot” (Bio Rad) on which strips of separate proteins 
Analysis Percentage of vaccinated volunteers with positive responses
Time after
the first vaccination, 
days
Time after the second vaccination, days
14 28 14 28 90 180 270 360
Neutralization of virusa B/SF162 — — 71 71 71 64 57 0
B/PVO4 — — 36 36 29 29 15 0
A/392 — — 86 86 86 71 57 0
A/SP2010 — — 79 79 79 64 7 0
IFN-γ ELISpotb 71 79 100 93 86 79 50 43
MHC pentamersc 100 100 100 100 80 100 80 60
aThe neutralization of virus was evaluated as IC50 value obtained by neutralizing the clones of pseudoviruses of subtypes 
A (SP-2010 and SP-392) and B (SF162 and PVO4) with blood sera of volunteers vaccinated with CombiHIVvac. The 
reaction was considered as positive if the neutralization titer was greater than or equal to 1: 100. The neutralizing 
activities of sera on the 14th and 28th days after immunization were lower than 1: 100.
bThe ELISpot responses were considered as positive if the number of IFN-γ-producing cells in the vaccinated volunteers 
was two times larger than the control value.
cThe results of determination of HIV-specific CD8+ T-lymphocytes in HLA-A*0201-positive volunteers repeatedly 
vaccinated with CombiHIVvac obtained with the use of MHC pentamers in a complex with Env peptide (KLTPLCVTL) 
of HIV-1 are given.
Table 1. Evaluation of the response of HIV-specific T-lymphocytes and the activity of virus-neutralizing antibodies in 
repeatedly vaccinated volunteers.
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of virus lysate were sorbed. Using immunoblot analysis, we demonstrated the presence of 
antibodies to HIV-1 proteins p17, p24, p55, p68, and gp120, i.e. to those proteins which epi-
topes compose B-cell vaccine component – TBI protein. The response rates differed among 
volunteers within the same group. Furthermore, during 1 year after the second immunization 
we registered antibodies at least to one of those proteins in 100% of volunteers.
The results of the study of T-cell response via the IFN-γ ELISpot in repeatedly vaccinated vol-
unteers (Table 1) show the HIV-specific response of T-lymphocytes in all volunteers (100%) 
on the 14th day after the first vaccination, remaining sufficiently strong for 6 months after the 
second vaccination. Using MHC pentamers in a complex with Env peptide (KLTPLCVTL, 
gp120 aa 120–128) of HIV-1, it was demonstrated that KLTPLCVTL CD8 T lymphocytes occur 
in all volunteers (100%) up to the sixth month after the second vaccination (Table 1).
Thus, the performed clinical trials showed that the CombiHIVvac vaccine is well tolerated and 
safe (does not induce any significant changes in biochemical and physiological parameters in 
comparison to the background values), characterized by low reactogenicity (local reactions to 
the vaccine are absent) and most importantly capable of inducing the specific humoral and 
cellular immunity.
Based on the obtained results, the Ministry of Health and Social Development of the Russian 
Federation has recommended the vaccine for advanced (Phase II) clinical trials.
4. Possible development of CombiHIVvac vaccine platform
Preclinical and clinical trials of CombiHIVvac demonstrated that a combination of two com-
pletely artificial polyepitope T- and B-cell antigens is capable of inducing HIV-specific CTLs 
and antibodies in laboratory animals and human. Furthermore, TCI protein expressed in 
cells as part of pcDNA-TCI plasmid fulfills a double function: (1) induces specific CD8+ CTL 
responses and (2) acts as an adjuvant synergistically effecting on synthesis of antibodies to 
TBI protein with virus-neutralizing activity at least to two HIV-1 subtypes (A and B) [23, 26].
The obtained results imply that CombiHIVvac is actually an original platform for the develop-
ment and further improvement of combined DNA-protein HIV-vaccines using a broad range 
of conservative T- and B-cell epitopes based on virus antigens. Providing that TBI and TCI 
immunogens in CombiHIVvac composition were developed more than 15 year ago concur-
rently with clinical trials of CombiHIVvac, we carried out works on enhancement of immu-
nogenic and protective properties of artificial polyepitope antigens utilizing new data on the 
structural-functional organization and immunology of HIV-1.
4.1. B-cell epitopes to HIV-1 generating broadly neutralizing antibodies (bNAbs)
At present when developing efficient B-cell immunogens, researchers mainly rely on epitopes 
recognized by antibodies neutralizing a broad spectrum of HIV-1 strains (bNAbs). In recent 
years dozens of B-cell HIV epitopes recognized by bNAbs have been detected [27].
It was shown that many of these antibodies can prevent infection, and some can suppress 
active infection in hu-mice or macaques [28–32]. Recently results of Phase I clinical trials of 
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mAbs VRC01 were published [33]. It is shown that they are safe and well tolerated after mul-
tiple intravenous or subcutaneous administrations in humans, in addition VRC01 from par-
ticipants’ sera were found to avidly capture HIV virions and to mediate antibody-dependent 
cellular phagocytosis [33].
Exceptional features of bNAbs inspire many researches to develop immunogen capable of 
their producing (induction). One of the evolving research areas focusing on the design of 
such immunogens is based on the development of HIV-1 envelope (Env) trimers [6, 34–36]. 
Despite substantial progress in this area, (a number of questions must be addressed). Firstly, 
although trimers are rather stable in solution, they produce conformational conditions that 
fail to provide binding and induction of bNAbs. Secondly, trimers expose undesired immuno-
dominant non-protective HIV epitopes that could prevent adaptive immune response from 
recognizing neutralizing epitopes, block protective immunity and/or induce increased HIV-
infection [4, 36].
An alternative approach to solving this problem includes constructing completely artificial 
polyepitope anti-HIV-1 immunogens comprising a set of protective epitopes assembled in 
a single mosaic (polyepitope) construct. Unfortunately, the most bNAbs recognize confor-
mational epitopes and considerably more rarely linear epitopes [37–39]. Furthermore, con-
formational B-cell epitopes are frequently formed in HIV by lipids and glycans or their 
combinations [37–40]. It complicates the design of immunogens capable of inducing sufficient 
B-cell response. Phage peptide libraries offer the unique possibility to obtain mimics of such 
epitopes [41–46].
Using phage peptide library  we can select peptides mimicking epitopes recognized by bnAbs, 
that make it possible to construct mosaic immunogen on their base to simultaneously induce 
several neutralizing antibodies [43, 47–52]. Figure 4 depicts general working scheme.
In our study we used a number of bNAbs against HIV-1, i.e. 2G12, 2F5, IgG1b12, Z13е1, 
VRC-01, VRC-03, and 697-30D to obtain peptide-mimics. The last five bNAbs were kindly fur-
nished upon NIH AIDS Reagent Program, USA. Each monoclonal antibody was used to per-
form biopanning using phage peptide libraries (New England Biolabs, USA) [20, 47, 48, 53].
After biopanning of phage libraries using monoclonal antibody 2G12 (recognizes confor-
mational epitope) and 2F5 (recognizes linear epitope), we isolated peptide-mimics that have 
another amino acid sequences compared to natural epitopes, but able to elicit antibodies in 
laboratory animals capable to compete with initial bNAbs and neutralizing the virus.
As a result we obtained a collection of phagotops carrying on their surface peptide-mimics 
of epitopes recognized by above mentioned bNAbs. Specific activity of selected peptides was 
studied both free and in the compound of phage particles. We carried out chemical synthesis 
of 134 free peptides. Evaluation of their capacity to compete with HIV-1 epitope for binding 
to monoclonal antibodies VRC-01, VRC-03, and IgG1b12 was carried out using pseudovirus 
particles in virus-neutralization assay. To study peptides immunogenicity in the compound 
of phage particles, the latter were produced in preparative amount using bacterial cells. We 
used the obtained samples to immunize laboratory animals from which we sampled sera to 
study their virus-neutralizing activity. It was shown that sera of rabbits immunized with a 
mix of bacteriophages are able to neutralize pseudotyped viruses obtained on the base of 
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HIV-1  subtypes A, B, and AG [20, 47, 48, 53]. Consequently, we succeeded to demonstrate 
immunologic imitation of conformational antigenic determinants, i.e. HIV-1 epitopes, by lin-
ear peptides. Obtained peptide-mimics are material that can serve as a basis for the develop-
ment of immunoprophylactic HIV-1 vaccine. Besides, peptides can be used when designing 
diagnostic systems for the detection of antibodies to HIV-1.
4.2. Design of polyepitope T-cell antigens
The progress in identification of T-cell epitopes as well as understanding mechanisms of pro-
cessing and presentation of antigens through MHC class I and II pathway make it possible to 
rational design artificial polyepitope vaccines [13, 54].
It is known that CTL recognizes viral protein-antigens synthesized inside the cell not as full-
length molecules but as short peptides (8–10 amino acid residues) in complex with MHC 
class I molecules. These short antigenic epitopes emerge from endogenously synthesized 
proteins due to proteasome-mediated processing and then are transported to the lumen of 
endoplasmic reticulum (ER) using transport proteins TAP (transporter associated with anti-
gen processing) where they bind to emerging MHC class I molecules [55, 56]. Since anti-
gen must be synthesized in a cell to induce response of CTL, target T-cell vaccine should be 
designed as DNA-vaccine because it is the most natural way of presenting CTL-epitopes to 
CD8+ T-lymphocytes through MHC class I pathway [57].
As opposed to stimulation of CTL, when inducing CD4+ T-lymphocyte-helpers response, 
antigen should be presented to these cells in a complex with MHC class II molecules. Usually 
Figure 4. Phage display applications for artificial immunogen design. (A) Randomized peptide library are used to 
map the residues forming the epitope(s) recognized by monoclonal antibodies immobilized on a solid support; (B) 
amplification of selected phages; (C) ELISA assay or western blot to determine specificity of selected phages binding; (D) 
phage particles are used to presentation isolated peptides-mimotopes to the immune system; (E) virus-neutralization 
assay of immune serum, selection of the most promising mimotope; (F) artificial immunogen design.
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 processing and presentation of antigen take place for extracellular antigens which are deliv-
ered in cells via endocytosis and phagocytosis. In this case antigen processing occurs in 
lysosome.
Thus, when designing polyepitope T-cell immunogens capable of inducing high levels of CD4+ 
and CD8+ T-lymphocyte responses to all epitopes in its compound, one should provide effi-
cient proteasome- and/or lysosome-mediated processing of expression product of target gene 
through MHC class I and II pathway. For the purpose the following strategies are appropriate:
1. To design poly-CTL-epitope construct one may use spacer sequences dividing epitopes 
that comprise sites of proteasomal cleavage [58–60] and/or motif for binding to TAP 
[61–63] to provide polyepitope processing and transport of released peptides (epitopes) 
into ER.
2. To induce T helper lymphocytes response fragments with T-helper epitopes can be com-
bined with the use of motif [KR][KR] which is a cleavage site for a number of lysosomal 
cathepsins participating in antigen processing [64, 65].
3. To target polyepitope immunogen into proteasome and presentation of CTL-epitopes to 
CD8+ T-lymphocytes through MHC class I pathway, researchers typically use genetic at-
tachment of ubiquitin sequence to its N- or C-termini [66].
4. To degrade polyepitope immunogen and present released Th-epitopes to CD4+ T-lympho-
cytes through MHC class II pathway, researchers typically use a genetic attachment of the 
sequence of LAMP-1 protein tyrosine motif (Lysosomal-associated membrane protein 1) 
to its C-terminus to direct the polyepitope immunogen from the secretory pathway to the 
lysosome [67–70].
To evaluate which of these strategies provide a rational approach to constructing T-cell antigens, 
we designed a set of polyepitope constructs covering a range of possible structural variants.
To assess the influence of ubiquitin and spacer sequences flanking epitopes on immunoge-
nicity of the polyepitope construct, we designed a set of polyepitope immunogens consider-
ing different strategies of processing and presentation of the target antigens. The designed 
constructs comprised similar set from 10 HLA-A2-restricted CTL-epitopes of the main HIV-1 
antigens Env, Gag, Pol, Nef, and Vpr, but differed in a number of structural properties, namely 
(i) the presence or absence of spacers; (ii) the structure of spacer sequences, and (iii) the pres-
ence of N- or C-terminal sequence of ubiquitin. Genes encoding the designed antigens were 
cloned into plasmid vector and vaccinia virus.
Immunogenicity of the designed immunogens were evaluated after 3-fold prime-boost 
immunization of HLA-A2 transgenic mice with the obtained recombinant plasmids and 
recombinant vaccinia virus (rVV). It was demonstrated that the vaccine construct inducing 
the majority of complexes [peptide/MHC class I] in vitro was also the most immunogenic 
during animal vaccination. This construct comprises N-terminal ubiquitin to target the poly-
epitope on proteasome. Besides, in the compound of this construct epitopes are divided by 
spacer sequences comprising sites of proteasomal cleavage of the polyepitope and motifs for 
TAP-dependent transport of the released peptides into ER where they bind to MHC class I 
molecules [54].
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The obtained results became the basis for the development of original software TEpredict and 
PolyCTLDesigner that we consider as a universal platform for rational design of polyepitope 
immunogens – candidate DNA vaccines for induction of T-cell immunity both against infec-
tious and oncological diseases [71, 72] (Figure 5).
PolyCTLDesigner enables the user to select a minimal set of epitopes with known or pre-
dicted specificity to different allelic variants of MHC class I molecules. This set covers selected 
repertoire of HLA alleles with the given degree of redundancy. After that PolyCTLDesigner 
uses the model by Peters et al. [73] to predict binding affinity to TAP for the selected set of 
known or predicted epitopes. According to this model, the main contribution into peptide 
binding to TAP is provided by the first three N-terminal amino acid peptide residues and 
the last C-terminal residue. Considering that epitope C-terminus must be unchanged since 
C-terminus should contain the site of proteasomal cleavage [74], only N-terminus of anti-
genic peptide can be extended (if necessary) for optimization of interaction with heterodimer 
TAP1/TAP2.
Then PolyCTLDesigner analyzes all possible matching of the selected peptides and detects an 
optimal spacer sequence for each pair providing adequate cleavage of epitopes with release of 
C-terminus of proximal peptide. To predict proteasomal and/or immunoproteasomal cleav-
age, PolyCTLDesigner uses models developed by Toes et al. [75].
When analyzing epitopes matching, PolyCTLDesigner creates a directed graph with nodes 
corresponding to epitopes and edges corresponding to acceptable matching. Each edge has 
relevant weight vector characterized by the efficiency of proteasomal cleavage, spacer length 
Figure 5. PolyCTLDesigner operation algorithm. I – Selection of minimal set of CD8+ T cell epitopes with the known 
or predicted specificity towards various allelic variants of MHC class I molecules; II – Prediction of binding affinity of 
peptides to TAP and, if necessary, addition of N-terminal flanking residues to optimize this binding; III – Prediction 
of optimal spacer sequences for each pair of peptides; IV – Creating weighted graph, where the nodes are the target 
epitopes, and the edges are possible variants of their association. Each edge is a weight vector whose attributes are: 
efficiency of proteasomal cleavage, length of the spacer, and number of predicted non-target epitopes at junction; V – 
Designing polyepitope immunogen sequence. Resulting sequence is defined as the longest simple path in the graph that 
has the lowest weight; Prot1, Prot2, Prot3 – proteasomal cleavage sites.
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and number of predicted non-target epitopes at the junction. Finally, the software designs an 
optimal polyepitope immunogen sequence that is calculated as a complete simple way in the 
constructed graph with the least length (weight).
Besides, PolyCTLDesigner makes it possible to construct a sequence of the epitope fragment 
comprising T-helper epitopes. In the compound of the selected antigens software predicts 
peptide fragments with the length of 20–40 amino acid residues with the majority of overlap-
ping T-helper epitopes restricted by the widest possible repertoire of HLA class II allomorphs. 
Then five C- and N-terminal amino acid residues from the initial antigen sequence are added 
to each of the selected fragments since it was shown that they can play significant role in bind-
ing to T-cell receptors of CD4+ T-lymphocytes [76, 77]. Fragments with T-helper epitopes are 
combined using [KR][KR] motif which is a cleavage site for a number of lysosomal cathepsins 
involved in antigen processing.
More detailed information on PolyCTLDesigner software is available at http://tepredict.
sourceforge.net/PolyCTLDesigner.html.
We used the developed software when designing new polyepitope constructs – candidate 
DNA-vaccines against HIV-1. Particularly, when evaluating the influence of proteasome-
dependent and lysosome-dependent degradation of polyepitopes on immunogenicity of the 
target polyepitope construct, we designed three polyepitope HIV-1 immunogens, i.e. TСI-N1, 
TСI-N2, and TСI-N3 using cytotoxic and helper T-cell epitopes of HIV-1 [78].
All three polyepitope immunogens are based on the same core sequence of polyE, while differences 
between immunogens lie in the use of different terminal signal sequences (Figure 6). Immunogen 
TCI-N1 comprises only the core sequence polyE. Sequence polyE of TCI-N2  immunogen includes 
Figure 6. Design of T-cell polyepitope immunogens. polyE – common for all antigens sequence polyE designed using 
cytotoxic and helper T-cell epitopes of HIV-1; ER-signal – N-terminal signal peptide (in our case MRYMILGLLALAAVCSAA 
– the signal sequence of the adenovirus protein E3/gp19K); LAMP1 – C-terminal tyrosine-based motif of LAMP-1 
glycoprotein (RKRSHAGYQTI); Ub – N-terminal ubiquitin with substitution of the C-terminal Gly to Val to prevent 
liberation of Ub cleavage by Ub hydrolases.
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N-terminal signal peptide and C-terminal tyrosine motif of LAMP-1 protein. N-terminal signal 
peptides are believed to provide delivery of immunogen in ER, while LAMP-1 protein motif 
directs immunogen from the secretory pathway to the lysosome and presents epitopes released 
after the cleavage to CD4+ T-lymphocytes through MHC class II pathway. The sequence polyE 
of TCI-N3 comprises N-terminal ubiquitin for its delivery into proteasome and presentation of 
epitopes released after the cleavage to CD8+ T-lymphocytes through MHC class I pathway.
Immunogenicity of the obtained DNA-vaccine constructs was studied in BALB/c mice according 
to capacity of CD4+ and CD8+ T-cells to produce IL-2 and IFNγ in ELISpot. The obtained results 
revealed that DNA-vaccine constructs encoding TCI-N2 and TCI-N3 immunogens induce 
responses of HIV-specific CD4+ and CD8+ T-lymphocytes that are significantly higher than that 
of the negative control the group of animals immunized with vector plasmid pcDNA3.1 as well 
as of group of mice that received a construct encoding core immunogen TCI-N1 with no addi-
tional signal sequences. At the same time DNA-vaccine construct encoding TCI-N3 immunogen 
comprising N-terminal ubiquitin induces the highest statistically significant level (Р ≤ 0.05) of 
CD4+ and CD8+ T-lymphocytes as compared with two other immunogens.
Thus, the obtained results point to a regular correlation between the structure of polyepitope 
construct and its antigenic and immunogenic properties:
• it is possible to significantly increase the immunogenic potential of the target polyepitope 
vaccine via optimization of the immunogen structure using the spacer sequences compris-
ing motifs for binding to TAP and the sites of proteasomal and lysosomal cleavage flanking 
CTL- and Th-epitopes in the compound of the polyepitope construct;
• ubiquitin-dependent targeting of polyepitope at proteasome is the most efficient strategy to in-
duce specific T-cell immune response as compared to LAMP-dependent targeting at lysosome.
Our findings support the concept of vaccine rational design based on existing knowledge on 
mechanism of presentation of T-cell antigens through MHC class I and II pathway.
5. Conclusions
We did not set ourselves the task of covering all challenges facing designers of HIV-1 vaccine. 
The paper presents our experience on designing artificial polyepitope HIV-1 immunogens 
constructed using a broad spectrum of conservative T- and B-cell epitopes. This approach 
is believed to be promising for the design of new generation HIV-vaccines. In theory, it 
makes it possible to overcome HIV-1 antigenic variability, focuses immune responses on 
protective determinants, and allows to exclude from vaccine composition undesired deter-
minants capable of inducing autoantibodies or antibodies increasing virus infectivity. The 
results demonstrate that completely artificial molecules designed with the use of bioin-
formatic and combinatorial biology methods are able to induce production of broad-spec-
trum neutralizing antibodies and responses of cytotoxic (CD8+ CTL) and helper (CD4+ Th) 
T-lymphocytes in laboratory animals and human.
It is our belief that the proposed approach can play an important and positive role in the 
development of HIV-1 vaccine.
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